- Home
- IART vs PHAR Comparison
IART vs PHAR Comparison
Compare IART & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IART | PHAR |
|---|---|---|
| Founded | 1989 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.9M | 1.1B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IART | PHAR |
|---|---|---|
| Price | $10.45 | $16.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $14.83 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 688.6K | 30.1K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | $27.75 |
| Revenue Next Year | $3.57 | $9.39 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.60 | $7.50 |
| 52 Week High | $24.37 | $21.34 |
Technical Indicators
Market Signals| Indicator | IART | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 42.99 |
| Support Level | N/A | $15.72 |
| Resistance Level | $14.14 | $16.29 |
| Average True Range (ATR) | 0.60 | 0.60 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 4.50 | 44.02 |
Price Performance
Historical ComparisonAbout IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.